文献速递主动脉疾病

评估肥胖对腹主动脉瘤治疗结局影响的系统综述与荟萃分析

A systematic review and meta-analysis evaluating the impact of obesity on outcomes of abdominal aortic aneurysm treatment.
PubMed 文献 · J Vasc Surg · 2021-11-14

该系统综述与荟萃分析纳入7项观察性研究共14,971例患者(EVAR 11,743例,OSR 3,228例),评估肥胖对腹主动脉瘤治疗30天结局的影响。肥胖患者行EVAR的30天死亡率低于非肥胖患者,行OSR时死亡率和非肥胖患者相似但伤口并发症更高;肥胖患者中EVAR较OSR的30天死亡率和并发症更低。

要点

  • 肥胖患者行EVAR的30天死亡率低于非肥胖患者(1.5% vs 2.2%,OR 0.69)。
  • 肥胖患者行OSR的30天死亡率与非肥胖患者相似,但伤口并发症更高(OR 2.30)。
  • 肥胖患者中EVAR较OSR的30天死亡率更低(1.5% vs 5.0%,OR 0.23)。

核心结论

  • 肥胖患者行EVAR的30天死亡率低于非肥胖患者。
  • 肥胖患者行OSR的30天死亡率与非肥胖患者相似,但伤口并发症更高。
  • 肥胖患者在EVAR和OSR中其他心肺并发症发生率与非肥胖患者相似。
  • 肥胖患者中EVAR较OSR的30天死亡率和并发症更低,本研究提示EVAR优于OSR。

研究设计与样本

  • 系统综述与荟萃分析,纳入7项观察性研究,共14,971例患者(EVAR 11,743例,OSR 3,228例)。
  • 纳入标准为报告肥胖患者(体重指数≥30 kg/m2)腹主动脉瘤治疗围手术期(30天)结局的研究。
  • 主要结局为30天死亡率,次要结局包括30天心脏、呼吸、伤口、肾脏和神经系统并发症。

主要发现

  • 肥胖患者行EVAR的30天死亡率为1.5%,低于非肥胖患者的2.2%(OR 0.69,95%CI 0.50-0.96,P=0.03,I2=0%,证据等级低)。
  • 肥胖患者行OSR的30天死亡率为5.0%,与非肥胖患者的5.7%相似(OR 0.92,95%CI 0.70-1.20,P=0.54,I2=0%,证据等级低)。
  • 肥胖患者行OSR的伤口并发症高于非肥胖患者(OR 2.30,95%CI 1.74-3.06,P<0.001,I2=0%,证据等级低)。
  • 肥胖患者中EVAR的30天死亡率为1.5%,低于OSR的5.0%(OR 0.23,95%CI 0.12-0.46,P<0.001,I2=38%,证据等级低)。
  • 肥胖患者中EVAR的心脏、呼吸、伤口、肾脏和神经系统并发症也减少。

局限性

  • 纳入研究均为观察性研究,证据等级低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to evaluate the impact of obesity on perioperative mortality and complication rates in patients undergoing endovascular aortic repair (EVAR) and open surgical repair (OSR) for abdominal aortic aneurysms. METHODS: A systematic review of all studies reporting abdominal aortic aneurysm treatment perioperative (30-day) outcomes in obese patients (body mass index ≥30 kg/m2). The primary outcome was 30-day mortality. Secondary outcomes included cardiac complications, respiratory complications, wound complication, renal complications, and neurological complications at 30 days. These outcomes were pooled for meta-analysis. Analysis first compared obese vs nonobese patients undergoing EVAR and OSR then compared EVAR with OSR in obese patients. RESULTS: We identified seven observational studies with 14,971 patients (11,743 EVAR, 3228 OSR). Obese patients undergoing EVAR had lower 30-day mortality (1.5%) compared with nonobese patients (2.2%) (odds ratio [OR], 0.69; 95% confidence interval [CI], 0.50-0.96; P = .03; I2 = 0%; Grade of evidence: low). In OSR, obese patients (5.0%) had similar 30-day mortality to nonobese patients (5.7%) (OR, 0.92; 95% CI, 0.70-1.20; P = .54; I2 = 0%; Grade of evidence: low). Wound complications were higher in obese patients undergoing OSR (OR, 2.30; 95% CI, 1.74-3.06; P < .001; I2 = 0%; Grade of evidence: low). EVAR was associated with a lower 30-day mortality (1.5%) compared with OSR (5.0%) in obese patients (OR, 0.23; 95% CI, 0.12-0.46; P < .001; I2 = 38%; Grade of evidence: low). Cardiac, respiratory, wound, renal, and neurological complications were also reduced in EVAR. CONCLUSIONS: Obese patients have lower 30-day mortality in EVAR compared with nonobese patients. In OSR, obese patients had similar 30-day mortality but higher wound complications compared with nonobese patients. Obese patients otherwise have similar cardiopulmonary complication rates compared with nonobese patients in both EVAR and OSR. EVAR offers lower 30-day mortality and morbidity compared with OSR in obese patients. This study suggests that EVAR is superior to OSR in obese patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Naiem AA, Kim AY, Mahmoud I, et al. A systematic review and meta-analysis evaluating the impact of obesity on outcomes of abdominal aortic aneurysm treatment. J Vasc Surg. 2021. PMID: 34785300. doi:10.1016/j.jvs.2021.10.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。